A cis and trans adenine-dependent hairpin ribozyme against Tpl-2 target

Biochimie

Volumn 89, Issue 10, 2007, Pages 1257-1263

  Li, Y L ^a   Torchet, C ^a   Vergne, J ^a   Maurel, M C ^a  

^a INSTITUT JACQUES MONOD   (France)

Author keywords

Adenine; Cancer; cis Hairpin ribozyme; Tpl 2 gene; trans Hairpin ribozyme

Indexed keywords

ADENINE; ADENINE DEPENDENT HAIRPIN RIBOZYME 1; DNA; MITOGEN ACTIVATED PROTEIN KINASE; RIBOZYME; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; CIS TRANS ISOMERISM; COMBINATORIAL CHEMISTRY; DNA MODIFICATION; DOWN REGULATION; ENZYME ACTIVE SITE; GENE CONSTRUCT; GENE EXPRESSION REGULATION; GENE SILENCING; MOLECULAR STABILITY; NUCLEOTIDE SEQUENCE; PH MEASUREMENT; PROTEIN FUNCTION; START CODON;

ADENINE; ANIMALS; BASE SEQUENCE; CATALYSIS; HUMANS; HYDROGEN-ION CONCENTRATION; MAGNESIUM; MAP KINASE KINASE KINASES; MOLECULAR SEQUENCE DATA; NEOPLASMS; NUCLEIC ACID CONFORMATION; PROTO-ONCOGENE PROTEINS; RNA, CATALYTIC; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 34848918136     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2007.07.002     Document Type: Article

References (29)

1. Jarad G., Simske J.S., Sedor J.R., and Schelling J.R. Nucleic acid-based techniques for post-transcriptional regulation of molecular targets. Curr. Opin. Nephrol. Hypertens. 12 (2003) 415-421
2. Khan A.U. Ribozyme: a clinical tool. Clin. Chim. Acta 367 (2006) 20-27
3. Tafech A., Bassett T., Sparanese D., and Lee C.H. Destroying RNA as a therapeutic approach. Curr. Med. Chem. 13 (2006) 863-881
4. Buzayan J.M., Gerlach W.L., and Bruening G. Satellite tobacco ringspot virus RNA: A subset of the RNA sequence is sufficient for autolytic processing. Proc. Natl. Acad. Sci. USA 83 (1986) 8859-8862
5. Hutchins C.J., Rathjen P.D., Forster A.C., and Symons R.H. Self-cleavage of plus and minus RNA transcripts of avocado sunblotch viroid. Nucleic Acids Res. 14 (1986) 3627-3640
6. Hotchkiss G., Maijgren-Steffensson C., and Ahrlund-Richter L. Efficacy and mode of action of hammerhead and hairpin ribozymes against various HIV-1 target sites. Mol. Ther. 10 (2004) 172-180
7. Bartolome J., Castillo I., and Carreno V. Ribozymes as antiviral agents. Minerva Med. 95 (2004) 11-24
8. Opalinska J.B., and Gewirtz A.M. Nucleic-acid therapeutics: basic principles and recent applications. Nat. Rev. Drug Discov. 1 (2002) 503-514
9. Sullenger B.A., and Gilboa E. Emerging clinical applications of RNA. Nature 418 (2002) 252-258
10. Usman N., and Blatt L.M. Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics. J. Clin. Invest. 106 (2000) 1197-1202
11. Ojwang J.O., Hampel A., Looney D.J., Wong-Staal F., and Rappaport J. Inhibition of human immunodeficiency virus type 1 expression by a hairpin ribozyme. Proc. Natl. Acad. Sci. USA 89 (1992) 10802-10806
12. Thybusch-Bernhardt A., Aigner A., Beckmann S., Czubayko F., and Juhl H. Ribozyme targeting of HER-2 inhibits pancreatic cancer cell growth in vivo, Eur. J. Cancer 37 (2001) 1688-1694
13. Hampel A., and Tritz R. RNA catalytic properties of the minimum (-)sTRSV sequence. Biochemistry 28 (1989) 4929-4933
14. Fedor M.J. Structure and function of the hairpin ribozyme. J. Mol. Biol. 297 (2000) 269-291
15. Meli M., Vergne J., and Maurel M.C. In vitro selection of adenine-dependent hairpin ribozymes. J. Biol. Chem. 278 (2003) 9835-9842
16. Ceci J.D., Patriotis C.P., Tsatsanis C., Makris A.M., Kovatch R., Swing D.A., Jenkins N.A., Tsichlis P.N., and Copeland N.G. Tpl-2 is an oncogenic kinase that is activated by carboxy-terminal truncation. Genes Dev. 11 (1997) 688-700
17. Patriotis C., Makris A., Chernoff J., and Tsichlis P.N. Tpl-2 acts in concert with Ras and Raf-1 to activate mitogen-activated protein kinase. Proc. Natl. Acad. Sci. USA 91 (1994) 9755-9759
18. Salmeron A., Ahmad T.B., Carlile G.W., Pappin D., Narsimhan R.P., and Ley S.C. Activation of MEK-1 and SEK-1 by Tpl-2 proto-oncoprotein, a novel MAP kinase kinase kinase. EMBO J. 15 (1996) 817-826
19. Sourvinos G., Tsatsanis C., and Spandidos D.A. Overexpression of the Tpl-2/Cot oncogene in human breast cancer. Oncogene 18 (1999) 4968-4973
20. Komatsu Y., Nobuoka K., Karino-Abe N., Matsuda A., and Ohtsuka E. In vitro selection of hairpin ribozymes activated with short oligonucleotides. Biochemistry 41 (2002) 9090-9098
21. Joseph S., and Burke J.M. Optimization of an anti-HIV hairpin ribozyme by in vitro selection. J. Biol. Chem. 268 (1993) 24515-24518
22. Hampel A., Tritz R., Hicks M., and Cruz P. 'Hairpin' catalytic RNA model: evidence for helices and sequence requirement for substrate RNA. Nucleic Acids Res. 18 (1990) 299-304
23. Kijima H., and Scanlon K.J. Ribozyme as an approach for growth suppression of human pancreatic cancer. Mol. Biotechnol. 14 (2000) 59-72
24. Sandberg J.A., Sproul C.D., Blanchard K.S., Bellon L., Sweedler D., Powell J.A., Caputo F.A., Kornbrust D.J., Parker V.P., Parry T.J., and Blatt L.M. Acute toxicology and pharmacokinetic assessment of a ribozyme (ANGIOZYME) targeting vascular endothelial growth factor receptor mRNA in the cynomolgus monkey. Antisense Nucleic Acid Drug Dev. 10 (2000) 153-162
25. Mandal M., and Breaker R.R. Adenine riboswitches and gene activation by disruption of a transcription terminator. Nat. Struct. Mol. Biol. 11 (2004) 29-35
26. Hampel A., and Cowan J.A. A unique mechanism for RNA catalysis: the role of metal cofactors in hairpin ribozyme cleavage. Chem. Biol. 4 (1997) 513-517
27. Young K.J., Gill F., and Grasby J.A. Metal ions play a passive role in the hairpin ribozyme catalysed reaction. Nucleic Acids Res. 25 (1997) 3760-3766
28. Nesbitt S., Hegg L.A., and Fedor M.J. An unusual pH-independent and metal-ion-independent mechanism for hairpin ribozyme catalysis. Chem. Biol. 4 (1997) 619-630
29. Siwkowski A., Humphrey M., De-Young M.B., and Hampel A. Screening for important base identities in the hairpin ribozyme by in vitro selection for cleavage. Biotechniques 24 (1998) 278-284